Lyell Immunopharma's 15min chart triggers RSI Overbought, Bollinger Bands Narrowing.

Lyell Immunopharma's 15-minute chart has triggered a reading of overbought conditions on the Relative Strength Index (RSI) and narrowing Bollinger Bands at 08/19/2025 15:30. This suggests that the stock price has risen too quickly and exceeds fundamental support levels, with a decreasing magnitude of price fluctuations.

Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company focusing on next-generation CAR T-cell therapies for cancer patients, has reported its second-quarter 2025 financial results and business highlights. The company announced positive new clinical data, initiated a pivotal trial, and secured a significant private placement to support its pipeline development.

Lyell's lead clinical program, LYL314, demonstrated high rates of durable complete responses in a Phase 1/2 trial for the treatment of aggressive large B-cell lymphoma (LBCL). The company initiated the PiNACLE pivotal trial of LYL314 in patients with LBCL receiving treatment in the third- or later-line (3L+) setting and remains on track to initiate a pivotal trial in the second-line (2L) setting by early 2026.

In July, Lyell entered into a securities purchase agreement for a private placement, raising up to approximately $100 million in gross proceeds. The initial closing of approximately $50 million occurred on July 25, 2025. The company expects to use these funds, along with its existing cash, to advance two pivotal-stage clinical trials of LYL314 and for general corporate purposes.

The company reported a net loss of $42.7 million for the second quarter ended June 30, 2025, compared to a net loss of $45.8 million for the same period in 2024. Non-GAAP net loss decreased to $37.8 million, primarily driven by lower interest income and reduced cash balances.

Lyell's financial results and clinical milestones underscore the company's progress in developing innovative CAR T-cell therapies for cancer patients. The company's strong pipeline and strategic funding position it well to continue advancing its clinical programs.

References:
[1] https://www.globenewswire.com/news-release/2025/08/12/3132110/0/en/Lyell-Immunopharma-Reports-Business-Highlights-and-Financial-Results-for-the-Second-Quarter-2025.html